Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8017729 | 0.82 | OPRM1 (0.51) | MAOBMAOAOPRM1HSD11B1 | |
| SCHEMBL724856 | 0.82 | OPRM1 (0.34) | OPRM1 | |
| SCHEMBL4201312 | 0.81 | OPRM1 (0.46) | OPRM1ALDH1A1CYP2D6HSD11B1NPC1 | |
| SCHEMBL17316802 | 0.80 | OPRM1 (0.32) | OPRM1 | |
| SCHEMBL16701145 | 0.78 | OPRM1 (0.35) | MAOBMAOAOPRM1ALDH1A1CYP2D6 | |
| SCHEMBL21874151 | 0.78 | MAOB (0.46) | MAOBMAOAOPRM1ALDH1A1CYP2D6 | |
| SCHEMBL1019298 | 0.78 | ALDH1A1 (0.49) | OPRM1ALDH1A1NPC1LMNATP53 | |
| SCHEMBL1558872 | 0.78 | MAOB (0.36) | MAOBMAOAOPRM1ALDH1A1CYP2D6 | |
| SCHEMBL623955 | 0.78 | ALDH1A1 (0.46) | OPRM1ALDH1A1CYP2D6HSD11B1NPC1 | |
| SCHEMBL1021622 | 0.76 | ALDH1A1 (0.48) | OPRM1ALDH1A1HSD11B1NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11969425-B2 | Inhibitor of indoleamine-2,3-dioxygenase (IDO) | INVENTISBIO LLC (US) | 2024-04-30 | — | — | US | disclosed |
| CN-113896685-B | Indoleamine-2, 3-dioxygenase (IDO) inhibitors | 益方生物科技(上海)股份有限公司 | 2024-02-06 | — | — | CN | disclosed |
| US-20230338373-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO LLC | 2023-10-26 | — | — | US | disclosed |
| US-20230338373-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO LLC | 2023-10-26 | — | — | US | disclosed |
| EP-3414224-B1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO LLC (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20220054486-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO LLC (US) | 2022-02-24 | — | — | US | disclosed |
| US-20220054486-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO LLC (US) | 2022-02-24 | — | — | US | disclosed |
| CN-113896685-A | Indoleamine-2, 3-dioxygenase (IDO) inhibitors | 益方生物科技(上海)股份有限公司 | 2022-01-07 | — | — | CN | disclosed |
| US-10980807-B2 | Inhibitor of indoleamine-2,3-dioxygenase (IDO) | INVENTISBIO LLC (US) | 2021-04-20 | — | — | US | disclosed |
| US-10980807-B2 | Inhibitor of indoleamine-2,3-dioxygenase (IDO) | INVENTISBIO LLC (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200046697-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO LLC | 2020-02-13 | — | — | US | disclosed |
| US-20200046697-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO LLC | 2020-02-13 | — | — | US | disclosed |
| EP-3414224-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | Inventisbio Inc. (KY) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017139414-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO INC. (KY) | 2017-08-17 | — | — | WO | disclosed |
| WO-2017139414-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO INC. (KY) | 2017-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338373-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | IDO1, IDO2, INMT | MAOB 11/4885MAOA 10/4885OPRM1 1965/4885 |
| US-11969425-B2 | Inhibitor of indoleamine-2,3-dioxygenase (IDO) | IDO1, IDO2, INMT | MAOB 11/4885MAOA 10/4885OPRM1 1965/4885 |
| US-20220054486-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | IDO1, IDO2, INMT | MAOB 11/4885MAOA 10/4885OPRM1 1965/4885 |
| US-20200046697-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | IDO1, IDO2, INMT | MAOB 11/4885MAOA 10/4885OPRM1 1965/4885 |
| US-10980807-B2 | Inhibitor of indoleamine-2,3-dioxygenase (IDO) | IDO1, IDO2, INMT | MAOB 11/4885MAOA 10/4885OPRM1 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.